Skip to main content
Premium Trial:

Request an Annual Quote

Ontera, QuantuMDx Partner on Sepsis Test Development

NEW YORK – Santa Cruz, California-based Ontera and Newcastle upon Tyne, UK-based QuantuMDx said Tuesday that they are collaborating to develop technology for the detection of bloodstream infections and drug-resistance.

The technology will use QuantuMDx’s rapid cell/sample preparation technology, Capture-XT, and Ontera’s nanopore biosensor. The combined technologies may enable clinicians to interrogate blood specimens of people presenting with signs and symptoms of sepsis, allowing guided-care management at the bedside. It may also enable the identification of sepsis and resistance to most common antibiotics in less than 30 minutes, the firms said.

Financial and other terms of the collaboration were not disclosed.

QuantuMDx’s Capture-XT technology in development captures, concentrates, and enriches targeted pathogens from a large sample volume, quickly enabling visual diagnosis and downstream use in applications such as drug-susceptibility analysis, PCR, NGS, and, with this collaboration, nanopore detection, according to the partners.

Ontera’s single-pore platform in development provides fast amplification of multiple bacterial targets and differentiation between antibiotic resistant and susceptible strains. The company's silicon nanopore technology enables quantitative measurement of nucleic acids, proteins, and small molecules in minutes, avoiding time-consuming laboratory procedures that can delay precise treatment, they added.

QuantumMDx Chief Scientific Officer Jonathan O’Halloran said in a statement that its "early prototype testing has already shown sensitivity in the range required for this kind of test and [is] performed in minutes from spiked bacteria in whole blood."

Last month, QuantuMDx and SpeeDx announced a collaboration with the Foundation for Innovative New Diagnostics (FIND) to assess the feasibility of porting SpeeDx sexually transmitted infection tests to the QuantuMDx point-of-care testing device.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.